Exact Sciences Q4 EPS Estimate Reduced by Leerink Partnrs

Exact Sciences Co. (NASDAQ:EXAS) – Stock analysts at Leerink Partnrs decreased their Q4 2024 earnings estimates for Exact Sciences in a report released on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now forecasts that the medical research company will earn ($0.31) per share for the quarter, down from their prior estimate of ($0.30). The consensus estimate for Exact Sciences’ current full-year earnings is ($1.10) per share. Leerink Partnrs also issued estimates for Exact Sciences’ Q2 2025 earnings at $0.02 EPS.

Exact Sciences (NASDAQ:EXAS) last posted its quarterly earnings data on Tuesday, November 5th. The medical research company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). The company had revenue of $708.66 million for the quarter, compared to analyst estimates of $716.80 million. Exact Sciences had a negative return on equity of 6.17% and a negative net margin of 7.95%. The business’s revenue was up 12.8% compared to the same quarter last year.

A number of other equities research analysts have also recently commented on EXAS. Evercore ISI reduced their target price on shares of Exact Sciences from $80.00 to $60.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. Bank of America reduced their target price on shares of Exact Sciences from $75.00 to $72.00 and set a “buy” rating for the company in a research report on Friday, December 13th. TD Cowen increased their target price on shares of Exact Sciences from $82.00 to $86.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. Barclays assumed coverage on shares of Exact Sciences in a research report on Thursday. They issued an “overweight” rating and a $70.00 target price for the company. Finally, Benchmark reiterated a “buy” rating and issued a $65.00 target price on shares of Exact Sciences in a research report on Monday, January 13th. One investment analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. According to MarketBeat.com, Exact Sciences has an average rating of “Moderate Buy” and a consensus price target of $72.76.

Exact Sciences Stock Performance

NASDAQ:EXAS opened at $54.79 on Thursday. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.93 and a current ratio of 2.12. The company has a fifty day moving average of $57.32 and a two-hundred day moving average of $59.35. The stock has a market capitalization of $10.14 billion, a PE ratio of -46.83 and a beta of 1.24. Exact Sciences has a fifty-two week low of $40.62 and a fifty-two week high of $79.62.

Institutional Trading of Exact Sciences

Hedge funds have recently added to or reduced their stakes in the company. WCM Investment Management LLC lifted its position in shares of Exact Sciences by 1,153.2% during the 3rd quarter. WCM Investment Management LLC now owns 187,807 shares of the medical research company’s stock worth $12,388,000 after buying an additional 172,821 shares during the last quarter. Simplify Asset Management Inc. lifted its position in shares of Exact Sciences by 67.5% during the 3rd quarter. Simplify Asset Management Inc. now owns 29,277 shares of the medical research company’s stock worth $1,994,000 after buying an additional 11,800 shares during the last quarter. Zacks Investment Management purchased a new stake in shares of Exact Sciences during the 3rd quarter worth approximately $2,083,000. Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Exact Sciences by 59.5% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 335,705 shares of the medical research company’s stock worth $22,868,000 after buying an additional 125,192 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Exact Sciences by 3.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,292,090 shares of the medical research company’s stock worth $88,017,000 after buying an additional 45,015 shares during the last quarter. Institutional investors and hedge funds own 88.82% of the company’s stock.

Insider Activity at Exact Sciences

In other news, CEO Kevin T. Conroy bought 19,500 shares of Exact Sciences stock in a transaction that occurred on Wednesday, November 13th. The shares were purchased at an average price of $51.35 per share, with a total value of $1,001,325.00. Following the completion of the acquisition, the chief executive officer now directly owns 1,074,191 shares in the company, valued at $55,159,707.85. The trade was a 1.85 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 1.36% of the stock is owned by corporate insiders.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.